Skip to main content
European Commission logo
italiano italiano
CORDIS - Risultati della ricerca dell’UE
CORDIS
CORDIS Web 30th anniversary CORDIS Web 30th anniversary
Contenuto archiviato il 2024-06-18

Metagenomics in Cardiometabolic Diseases

Obiettivo

METACARDIS applies a systems medicine multilevel approach to identify biological relationships between gut microbiota, assessed by metagenomics, and host genome expression regulation, which will improve understanding and innovative care of cardiometabolic diseases (CMD) and their comorbidities. CMD comprise metabolic (obesity, diabetes) and heart diseases characterized by a chronic evolution in ageing populations and costly treatments. Therapies require novel integrated approaches taking into account CMD natural evolution.

METACARDIS associates European leaders in metagenomics, who have been successful in establishing the structure of the human microbiome as part of the EU FP7 MetaHIT consortium, clinical and fundamental researchers, SME, patients associations and food companies to improve the understanding of pathophysiological mechanisms, prognosis and diagnosis of CMD.

We will use next-generation sequencing technologies and high throughput metabolomic platforms to identify gut microbiota- and metabolomic-derived biomarkers and targets associated with CMD risks. The pathophysiological role of these markers will be tested in both preclinical models and replication cohorts allowing the study of CMD progression in patients collected in three European clinical centres of excellence. Their impact on host gene transcription will be characterised in patients selected for typical features of CMD evolution. Application of computational models and visualisation tools to complex datasets combining clinical information, environmental patterns and gut microbiome, metabolome and transcriptome data is a central integrating component in the research, which will be driven by world leaders in metagenomic and functional genomic data analysis. These studies will identify novel molecular targets, biomarkers and predictors of CMD progression, paving the way for personalized medicine in CMD.

Campo scientifico

Not validated

Programma(i)

Argomento(i)

Invito a presentare proposte

FP7-HEALTH-2012-INNOVATION-1
Vedi altri progetti per questo bando

Meccanismo di finanziamento

CP-IP - Large-scale integrating project

Coordinatore

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Contributo UE
€ 2 562 788,00
Indirizzo
RUE DE TOLBIAC 101
75654 Paris
Francia

Mostra sulla mappa
Regione
Ile-de-France Ile-de-France Paris
Tipo di attività
Research Organisations
Contatto amministrativo
Akouavi Ekoue (Ms.)
Collegamenti
Costo totale
Nessun dato

Partecipanti (15)

Condividi questa pagina

Scarica

Ultimo aggiornamento: 6 Settembre 2024

Il mio fascicolo

Permalink: https://cordis.europa.eu/project/id/305312/it

European Union, 2024